Posted by Michael Wonder on 23 Jun 2017
AbbVie receives CHMP positive opinion for Maviret (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes
23 June 2017 - Maviret would also be an additional HCV treatment option for patients with specific treatment challenges, such as those with compensated cirrhosis, chronic kidney disease and genotype 3.
AbbVie today announced that the European CHMP of the EMA has granted a positive opinion recommending marketing authorization of Maviret (glecaprevir/pibrentasvir), an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus (HCV) infection.
If approved, Maviret will be a once-daily, ribavirin-free, 8-week option for patients without cirrhosis and who are new to treatment across all genotypes, who comprise the majority of people living with HCV. The European Commission will now review the CHMP opinion and a final decision is expected in Q3 2017.
